1. Academic Validation
  2. Human cytomegalovirus protein pUL36: A dual cell death pathway inhibitor

Human cytomegalovirus protein pUL36: A dual cell death pathway inhibitor

  • Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18771-18779. doi: 10.1073/pnas.2001887117.
Alice Fletcher-Etherington 1 Luis Nobre 1 Katie Nightingale 1 Robin Antrobus 1 Jenna Nichols 2 Andrew J Davison 2 Richard J Stanton 3 Michael P Weekes 4
Affiliations

Affiliations

  • 1 Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom.
  • 2 Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, United Kingdom.
  • 3 Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom.
  • 4 Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom; [email protected].
Abstract

Human cytomegalovirus (HCMV) is an important human pathogen and a paradigm of intrinsic, innate, and adaptive viral immune evasion. Here, we employed multiplexed tandem mass tag-based proteomics to characterize host proteins targeted for degradation late during HCMV Infection. This approach revealed that Mixed Lineage Kinase domain-like protein (MLKL), a key terminal mediator of cellular Necroptosis, was rapidly and persistently degraded by the minimally passaged HCMV strain Merlin but not the extensively passaged strain AD169. The strain Merlin viral inhibitor of Apoptosis pUL36 was necessary and sufficient both to degrade MLKL and to inhibit Necroptosis. Furthermore, mutation of pUL36 Cys131 abrogated MLKL degradation and restored Necroptosis. As the same residue is also required for pUL36-mediated inhibition of Apoptosis by preventing proteolytic activation of procaspase-8, we define pUL36 as a multifunctional inhibitor of both apoptotic and necroptotic cell death.

Keywords

MLKL; cell death; human cytomegalovirus; necroptosis; protein degradation.

Figures